TRACON Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Aggressively Buying

US gold futures traded slightly higher this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3

Value Exchange International

• The Trade: Value Exchange International, Inc. VEII Director Heng Fai Ambrose Chan bought a total of 20,000 shares at an average price of $0.17. To acquire these shares, it cost around $3.33 thousand.
• What’s Happening: The company’s shares gained around 14% over the past six months.
• What Value Exchange International Does: Value Exchange International Inc is a us-based software company. The company through its subsidiaries provides customer-centric hardware and software system solutions for the retail industry in China, Hong Kong, and Philippines.

Outlook Therapeutics

• The Trade: Outlook Therapeutics, Inc. OTLK Director Kurt Hilzinger acquired a total of 111,203 shares at an average price of $1.28. The insider spent around $142.51 thousand to buy those shares.
• What’s Happening: Outlook Therapeutics and AmerisourceBergen recently announced strategic commercialization agreement for ONS-5010 for the treatment of wet AMD.
• What Outlook Therapeutics Does: Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Tesla To $370? Plus HC Wainwright Slashes PT On This Stock By 67%

Don’t forget to check out our premarket coverage here .

TRACON Pharmaceuticals

• The Trade: TRACON Pharmaceuticals, Inc. TCON President and CEO Charles Theuer acquired a total of 5,000 shares at an average price of $1.67. To acquire these shares, it cost around $8.35 thousand.
• What’s Happening: TRACON Pharmaceuticals disclosed results of Independent Data Monitoring Committee review of 12 Week safety data from ENVASARC Phase 2 pivotal trial.
• What TRACON Pharmaceuticals Does: TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States.